New combo therapy aims to keep mesothelioma from coming back after surgery

NCT ID NCT05932199

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better with or without chemotherapy for people with pleural mesothelioma that can be surgically removed. The goal is to see if these treatments can keep the cancer from returning for at least a year after surgery. About 52 participants will receive either the immunotherapy alone or with chemo before surgery, and researchers will monitor safety and how well the cancer responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Baylor St Lukes

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Duke Cancer Institute

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.